Adaptive Biotechnologies (ADPT) Scheduled to Post Quarterly Earnings on Tuesday

Adaptive Biotechnologies (NASDAQ:ADPT) is scheduled to post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Adaptive Biotechnologies to post earnings of ($0.35) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Wednesday, February 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. The company had revenue of $45.78 million during the quarter, compared to the consensus estimate of $50.15 million. Adaptive Biotechnologies had a negative net margin of 132.29% and a negative return on equity of 53.65%. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock opened at $3.01 on Monday. Adaptive Biotechnologies has a fifty-two week low of $2.28 and a fifty-two week high of $9.08. The firm has a market capitalization of $443.58 million, a price-to-earnings ratio of -1.93 and a beta of 1.27. The stock’s fifty day moving average is $3.12 and its two-hundred day moving average is $3.92.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 48,673 shares of Adaptive Biotechnologies stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total value of $166,948.39. Following the completion of the sale, the chief executive officer now directly owns 2,576,701 shares of the company’s stock, valued at approximately $8,838,084.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Adaptive Biotechnologies news, President Julie Rubinstein sold 39,070 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $3.47, for a total transaction of $135,572.90. Following the completion of the sale, the president now directly owns 472,754 shares in the company, valued at $1,640,456.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Chad M. Robins sold 48,673 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $3.43, for a total transaction of $166,948.39. Following the sale, the chief executive officer now directly owns 2,576,701 shares of the company’s stock, valued at approximately $8,838,084.43. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 124,307 shares of company stock valued at $428,090. Company insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

ADPT has been the subject of several recent research reports. BTIG Research dropped their target price on shares of Adaptive Biotechnologies from $6.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, April 4th. The Goldman Sachs Group reduced their target price on Adaptive Biotechnologies from $11.00 to $5.00 and set a “neutral” rating on the stock in a research note on Friday, February 16th. Finally, JPMorgan Chase & Co. dropped their price target on Adaptive Biotechnologies from $11.00 to $8.00 and set an “overweight” rating for the company in a research report on Thursday, February 15th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average price target of $6.80.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.